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Abstract
Purpose To determine the anatomical and functional outcomes of an extended 6-month intravitreal anti-vascular endothelial
growth factor (anti-VEGF) upload in choroidal neovascularization (CNV) secondary to chronic central serous chorioretinopathy
(CSCR).
Methods A retrospective database analysis was performed applying the following inclusion criteria: (1) diagnosis of CSCR, (2)
diagnosis of secondary CNV, and (3) treatment of at least six consecutive injections of anti-VEGF. Outcome measures included
the change of central retinal subfield thickness, remodeling of the pigment epithelium detachments, and change in visual
function.
Results Twenty-one eyes of 21 patients were included. Mean patient age was 65 ± 8.3 years, and 35% of the patients (n = 8) were
female. Mean disease duration before diagnosis of CNV was 48 ± 25.3 months. Mean central retinal thickness decreased from
346 ± 61 to 257 ± 57 μm (p < 0.01) after the sixth injection while mean visual acuity improved from 0.65 ± 0.35 to 0.49 ± 0.29
(logMAR; p < 0.01). Of note, an extended upload of six as opposed to three injections yielded an additional mean central retinal
thickness reduction (280 ± 46 μm vs. 257 ± 57 μm, p = 0.038). Significant CNV remodeling was observed as a decrease in
pigment epithelium detachment (PED) vertical (p = 0.021) and horizontal diameter (p = 0.024) as well as PED height (p < 0.01).
Conclusion An extended anti-VEGF upload of six consecutive injections seems to be effective in inducing CNV remodeling and
fluid resorption in CNV complicating chronic CSCR.
Keywords Choroidal neovascularization . Central serous chorioretinopathy . Pachychoroid . Pachychoroid neovasculopathy .
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Introduction
Choroidal neovascularization (CNV) is a typical complication in
chronic central serous chorioretinopathy (CSCR) [1] and repre-
sents a major risk factor of poor visual outcome [2]. With central
serous chorioretinopathy being a disease of the so-called
pachychoroid spectrum [3], secondary CNV in CSCR can also
be termed pachychoroid neovasculopathy (PNV) [4]. In these
cases, CNVusually develops below the retinal pigment epitheli-
um (RPE) as type 1 CNV [5] and typically manifests on optical
coherence tomography as flat irregular pigment epithelium
detachments (PED) [6]. In rare cases, a type 2 CNV (above the
RPE) can develop additionally. The prevalence of type 1 CNVin
CSCR was long time underestimated. Newer data suggest that
about one-third of the often observed flat irregular PEDs contain
CNV [7]. In a long-term follow-up study of CSCR patients,
approximately 24% developed a secondary CNV after on aver-
age 17 years of disease duration [8].
Since the publication of the results of the MINERVA study,
intravitreal anti-vascular endothelial growth factor complexa-
tion (anti-VEGF) with ranibizumab has been the on-label first-
line treatment in secondary CNV due to chronic CSCR [9].
Other treatment options discussed and published include a
combined therapy consisting of anti-VEGF and half-fluence
photodynamic therapy (hf-PDT) [10] or a full-fluence photo-
dynamic therapy alone [11].
In neovascular AMD, anti-VEGF is routinely administered
with an upload of three injections, and further treatment is
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based mainly on the presence of macular fluid and pigment
epithelium detachment dynamics. Due to the underlying path-
ophysiology of pachychoroid disease, the AMD treatment
criteria however do not apply to neovascularization due to
CSCR, or, as recently termed, PNV. Firstly, PNV usually pre-
sents with type 1 CNV [6], which is known to show a weaker
response to anti-VEGF compared with type 2 lesions.
Secondly, subretinal fluid might be both caused by the under-
lying pachychoroid and the CNV [12]. Resultingly, as a third
caveat, an important treatment effect of anti-VEGF in
pachychoroid disease may lie within the induction of choroi-
dal thinning and reduction of choroidal hyperpermeability as
opposed to sole fluid reduction [13].
Due to these facts, it is currently unclear whether the effects
of anti-VEGF in neovascular CSCR result from CNV remod-
eling or are mainly caused by choroidal thinning and
subretinal fluid resolution. In analogy, it is unclear whether
CNV in central serous chorioretinopathy or PNV in general
requires a three-injection upload similar to AMD or might
even benefit from an extended upload, especially concerning
the anti-VEGF effect on the underlying choroidal thickening
and congestion. This study was designed to investigate the
anatomical and functional response of neovascular CSCR
and the associated CNV to an extended upload of six anti-




For this retrospective cohort study, the Smart Eye Database of
the Department of Ophthalmology of the university hospital,
Ludwig-Maximilians-University Munich, Germany, was
screened for patients who were treated with anti-VEGF for
secondary CNV between January 2016 and December 2018
[14]. The anti-VEGF agents used for the injections were
ranibizumab and aflibercept (off-label). Inclusion criteria for
this study were the following: (1) diagnosis of central serous
chorioretinopathy as a manifestation of pachychoroid disease,
(2) diagnosis of CNV complicating pachychoroid disease (de-
fining PNV), and (3) treatment of at least six consecutive
injections of anti-VEGF. Exclusion criteria were confounding
comorbidities (diabetic retinopathy, hereditary retinal disease,
diseases of the vitreoretinal interface, post-vitrectomized eyes,
optic media impeding sufficient image quality) and evidence
of polyps or aneurysmal choroidal vessels in indocyanine
green angiography (ICGA). This retrospective chart review
was conducted according to the regulations of the local ethics
committee and the study adhered to the tenets of the
Declaration of Helsinki.
Epidemiological data was obtained from each patient, in-
cluding age, gender, previous ocular comorbidities and proce-
dures, date of first diagnosis of CSCR, anti-VEGF injection
dates, number and type of anti-VEGF injections, and
corrected visual acuity converted into logarithm of the mini-
mum angle of resolution (LogMAR) at baseline, and each visit
for injections until the end of follow-up.
Multimodal imaging
Multimodal imaging included spectral domain optical coher-
ence tomography (SD-OCTon SPECTRALIS®HRA +OCT,
Heidelberg Engineering, Heidelberg, Germany) with acquisi-
tion of a volume scan (with and without enhanced-depth im-
aging mode, EDI®) at each visit. Central macular thickness
(CMT) was assessed in the central 1-mm-diameter circle of
the ETDRS grid using the thickness map generated by the
Spectralis Software (Heidelberg Eye Explorer 1.9.11.0,
Heidelberg, Germany). The vertical subretinal fluid (SRF) di-
ameter was manually measured as the distance between the
end of the outer segments and the RPE at the point of maxi-
mum fluid accumulation. Subfoveal choroidal thickness
(SFCT) was assessed by manually measuring the distance
between the Bruch’s membrane interface and the choroidal-
scleral interface under the center of the foveolar depression.
Diagnosis of type 1 CNV was obtained by fluorescein angi-
ography (FA) and ICGA (SPECTRALIS® HRA + OCT,
Heidelberg Engineering, Heidelberg, Germany) and/or optical
coherence tomography angiography (CIRRUS® 5000 with
Angioplex, Carl Zeiss Meditec, Oberkochen, Germany, and
SPECTRALIS® OCT Angiography Module, Heidelberg
Engineering, Heidelberg, Germany). In FA and ICGA, fea-
tures suggestive of neovascularization included neovascular
networks in the early phase of FA or ICGA, leakage on FA,
and a hyperfluorescent plaque on ICGA in the late phase pho-
tographs (Fig. 1). In cases where a clear CNV diagnosis could
not be achieved by angiography alone, optical coherence to-
mography angiography (OCTA) was added to aid in
diagnosis.
Anti-VEGF treatment
All patients received six consecutive injections of anti-VEGF
in a 4-weekly delivery scheme. Anti-VEGF agents used were
0.5 mg of ranibizumab (Lucentis®; Novartis Pharma AG,
Basel, Switzerland) or 2 mg of aflibercept (Eylea; Bayer
HealthCare Pharmaceuticals, Berlin, Germany). In cases of
non-response after six injections, patients were individually
consulted in a shared decision-making manner to either con-
tinue the first-line injection regimen or change to second-line
options including a switch of the anti-VEGF agent or the
addition of a half-dose PDT.
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Statistical analysis
All data was collected and preprocessed in Microsoft
Excel spreadsheets (version 16.24 for Mac; Microsoft,
Redmond, WA, USA). Statistical analysis was performed
in SPSS Statistics version 25 (IBM Corp., Armonk, NY,
USA). The level to indicate statistical significance was
defined as p < 0.05. The Shapiro-Wilk and Kolmogorov-
Smirnov tests were employed to test for normal distribu-
tion of the measured parameters within the study cohort.
The paired (samples) t test and the Wilcoxon signed-rank
sum test were employed to test for significant differences
during follow-up within study eyes depending on the
presence of a normal distribution. Repeated measure
analysis of variance (ANOVA) was used for comparing
measurements at baseline vs. after third injection and
after sixth injection. Graphs were plotted in Microsoft




By screening our database of 2498 patients treated with intra-
vitreal injections between January 2016 and December 2018,
140 patients treated with anti-VEGF injections for secondary
CNV complicating chronic CSC were identified. Of these, 21
eyes of 21 patients met the inclusion criteria as defined in
“Methods.” Mean patient age at the first injection was 65 ±
8.3 years (range 48–81 years), and 35% of the patients (n = 8)
were female. Mean disease duration before diagnosis of CNV
was 48 ± 25.3 months. Four patients (19%) had been treated
with a half-fluence photodynamic therapy prior to developing
the CNV. In one patient (4.8%), a recent administration of
inhaled steroids was documented. In all other patients, there
was no evidence of a recent (i.e., in the 6 months before
presentation) steroid medication. The diagnosis of CNV was
primarily based on the angiography (FA and ICGA) in
Fig. 1 Example of a 68-year-old patient affected by secondary choroidal
neovascularization in chronic central serous chorioretinopathy. a Infrared
reflectance. bHorizontal B-scan of optical coherence tomography (OCT)
centered to the fovea showing the typical flat irregular pigment epithelium
detachment (PED), also referred to as the “double layer sign.” c 3 × 3mm
enface OCT angiography showing the neovascular network in the PED
showed in image b. d Fluorescein angiography image of the macula at
5 min showing granular hyperfluorescence without significant
exsudation. e Indocyanine green angiography image of the macular at
5 min showing a discreet plaque sign
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combination with the corresponding OCT image. OCTAwas
added for initial diagnosis in 17 of the 21 eyes (81%) to con-
firm the diagnosis of a choroidal neovascularization.
Regarding the CNV characteristics, 18 eyes (86%) had a type
1 CNV (between the Bruch membrane and RPE), and three
eyes (14%) had a type 2 CNV (CNV reaching beyond the
RPE). Of the eyes with a type 2 CNV, in two cases, the emer-
gence of the type 2 CNV from a type 1 CNV had been ob-
served before initiating treatment, and one case was primarily
diagnosed with type 2 CNV. Two of the eyes with a type 2
CNV showed a subretinal hemorrhage on fundoscopy. Mean
subfoveal choroidal thickness at baseline was 330 ± 66 μm
(range 197–436 μm). Twelve eyes (57%) had a subfoveal
choroidal thickness over 300 μm.
Anti-VEGF treatment
All patients received 6-monthly injections. The mean interval
between injections was 34 ± 3 days. For the first injection, 16
patients received ranibizumab and 5 patients received
aflibercept. Two patients were switched from ranibizumab to
aflibercept after the third and fourth injection, respectively. No
patient was switched from aflibercept to ranibizumab during
the first six injections. No adverse events were recorded dur-
ing the observation period.
Anatomical outcomes
Mean central retinal thickness (CRT) decreased from 346 ±
61.0 (95% CI [319-374 μm]) to 257 ± 57.4 μm (p < 0.001)
after the sixth injection (Fig. 2). There was a significant further
reduction of mean CRT beyond the third injection (280 ±
45.6 μm vs. 257 ± 57.4 μm, p < 0.001) both globally when
comparing all three time points in a repeated measure
ANOVA as well as specifically when applying a Bonferroni
post hoc analysis with pairwise comparisons (BL vs. third
injection p < 0.001, third injection vs. sixth injection p =
0.038). The number of patients with a complete resolution of
subretinal fluid improved from 4 (19%) after the third injec-
tion to 11 (52.4%) after the sixth injection. This difference was
statistically significant (p = 0.024, chi-square test). 19 eyes
(90.5%) had a reduction of CRT after the sixth injection com-
pared with baseline. The remaining two patients (9.5%) who
had an increase of CRTcomparedwith baseline both showed a
recurrence of subretinal fluid under ongoing therapy.
During injection therapy, a marked decrease of pigment
epithelium detachment size and thickness was noted (Fig. 3,
Table 1). The mean horizontal and vertical diameter of PED
decreased from 1980 ± 543 μm and 1861 ± 658 μm to 1794 ±
614 μm and 1702 ± 586.7 μm, respectively (p = 0.024 and
p = 0.021). The horizontal and vertical PED diameter values
are for n = 19 eyes because in two eyes, the boundaries of the
PED were not demarcated clearly enough. All other measure-
ments were performed for all n = 21 eyes. The maximum PED
height decreased on average from 169 ± 77.6 at baseline to
137 ± 64.2 μm after the third injection (p = 0.01) and to
121.6 ± 56.3 μm (p < 0.001) after six injections. The
Fig. 3 Mean pigment epithelium detachment measurements. The left y-
axis indicates the size of vertical and horizontal diameter of the PED; the
mean was calculated from n = 19 measurements. The right y-axis
indicates the PED height (n = 21). All y values are in μm, and the error
bars indicate the standard error of the mean
Fig. 2 Change in mean central macular thickness with the number of
intravitreal injections. One asterisk indicates statistical significance of
p < 0.05; two asterisks indicate p < 0.01
Graefes Arch Clin Exp Ophthalmol (2020) 258:1013–10211016
difference between PED height after three vs. after six injec-
tions continued to be statistically significant (p = 0.029). The
maximum vertical diameter of the subretinal fluid accumula-
tion decreased on average from 117 ± 47.0 at baseline to 25 ±
36.5 μm after six injections (p < 0.001, Wilcoxon signed-rank
test). Subfoveal choroidal thickness decreased from an aver-
age 330 ± 66.4 at baseline to 311 ± 66.2 μm after three injec-
tions to 302 ± 69.6 μm after six injections. The difference
between all three time points was statistically significant with
p < 0.001. Furthermore, in pairwise comparisons, the differ-
ence between baseline and three injections as well as the dif-
ference between three injections and six injections was statis-
tically significant with p < 0.001 and p = 0.03, respectively.
When arranging those patients who only received
ranibizumab (14 eyes) and those who received aflibercept
from the beginning or were switched to aflibercept during
the extended upload (7 eyes) into subgroups, the results for
the reduction of the central retinal thickness were as follows:
In the ranibizumab group, a reduction of − 65 ± 59.2 μm was
observed while in the aflibercept group, the reduction was −
138 ± 52.5 μm. The percentage of complete resolution of
subretinal fluid was 43% (n = 6) in the ranibizumab group
and 71% (n = 5) in the aflibercept group. This difference
showed no statistical significance (p = 0.22).
Functional outcomes
Mean visual acuity improved from 0.65 ± 0.35 at baseline to
0.51 ± 0.29 after the third (p = 0.012) and 0.49 ± 0.29
logMAR (p = 0.011) after the sixth injection. There was no
significant additional increase in visual acuity between the
third and sixth injection (p = 0.72).
Discussion
The present study suggests that an extended upload of six
consecutive anti-VEGF injections is an effective treatment
for choroidal neovascularization secondary to CSCR. CNV
membranes secondary to CSCR are known to show a much
milder dynamic in contrast to their counterparts in neovascular
AMD, myopia, or other secondary causes. For this purpose,
this study sought to evaluate the specific responses of CNV
membranes secondary to CSCR. The data of this study sug-
gests that an extended upload with six consecutive anti-VEGF
injections is an effective treatment for these lesions. As a new
finding, a significant additional benefit of six over three initial
injections was observed on central retinal thickness, PED
thickness, and PED size.
As recently established by a growing body of evidence,
CSCR represents a disease within the new spectrum of
“pachychoroid disorders” [3], the exploration of which has
been made possible by advances in the visualization of the
choroid using enhanced-depth imaging mode on spectral do-
main OCT. These pachychoroid disorders include
pachychoroid pigment epitheliopathy (PPE), defined by char-
acteristic RPE changes without subretinal fluid, pachychoroid
neovasculopathy (PNV), defined by the formation of CNV
atop of a thickened choroid, and pachychoroid aneurysmal
type 1 CNV (pAT1-CNV, also termed polypoidal choroidal
vasculopathy, PCV), when formation of aneurysms within the
neovascularization occurs. As recently suggested, these four
diseases do not represent separate entities, but rather form a
continuum of one disease in four stages [15]. Beginning with
asymptomatic and uncomplicated choroidal thickening and
congestion, the pachychoroid disease then causes characteris-
tic RPE arrosions due to choroidal hyperpermeability, defin-
ing PPE as stage 1 disease. The disease can show progress into
stage 2 by formation of subretinal fluid, defining CSCR. This
stage can become chronic or recurrent and in complicated
cases progress to the neovascular stage 3, defining PNV. The
neovascularization can ultimately turn into pachychoroid an-
eurysmal type 1 CNV (pAT1-CNV/PCV), defined by the for-
mation of CNVaneurysms [16].
When CNVoccurs in central serous chorioretinopathy (i.e.,
pachychoroid neovasculopathy), anti-VEGF injections are the
treatment of choice for most ophthalmologists. To date, no
standard treatment algorithm for CNV in central serous
chorioretinopathy has been reported. Since the MINERVA
study, ranibizumab has been the first-line and on-label option
Table 1 Anatomical remodeling under anti-VEGF injection therapy. All values are listed as mean ± standard deviation. The p value in the last column
indicates the statistical significance for the difference between baseline and after six injections. PED, pigment epithelium detachment
Before treatment After three injections After six injections p
Mean central retinal thickness (μm) 346 ± 61.0 280 ± 45.6 257 ± 57.4 < 0.001
Mean subfoveal choroidal thickness (μm) 330 ± 66.4 311 ± 66.2 302 ± 69.6 < 0.001
Mean horizontal PED diameter (μm)* 1980 ± 543.3 1892 ± 581.3 1794 ± 614.0 0.024
Mean vertical PED diameter (μm)* 1861 ± 658.1 1760 ± 592.5 1702 ± 586.7 0.021
Mean maximum PED height (μm) 169 ± 77.6 137 ± 64.2 122 ± 56.3 < 0.001
Mean vertical SRF diameter (μm) 117 ± 47.0 58 ± 47.2 25 ± 36.5 < 0.001 (Wilcoxon)
*The mean values for the PED diameters are for n = 19; all other values are for n = 21
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for secondary CNV in many different disease conditions, in-
cluding CSCR [9]. Considering that CSCR is a common dis-
ease and CNV seems to be a natural complication of
prolonged disease course [8], there exists only little evidence
for treatment.
This study is the first study to describe the effects of a strict
upload of six anti-VEGF injections for secondary CNV in
CSCR. There have been reports of anti-VEGF treatment out-
comes in this disease condition before, albeit without the six-
injection upload. Chablani and colleagues have reported fa-
vorable outcomes of anti-VEGF treatment in 46 eyes regard-
ing treatment safety and visual acuity with a mean number of
4.45 ± 4.1 anti-VEGF injections during a mean follow-up pe-
riod of 38.3 ± 58.9 months [17]. The mean improvement of
visual acuity in their study was 1.16 ± 3.74 lines (Snellen)
which can be considered more or less comparable with the
observed mean improvement of 0.16 ± 0.26 logMAR in our
study. A publication evaluating a combined treatment of anti-
VEGF injections and half-fluence PDT showed favorable an-
atomical results with a mean of 1.8 ± 3.6 injections over the
12-month follow-up period [10]. Another publication com-
pared full-fluence PDT with intravitreal anti-VEGF agents
and reported a more marked decrease in central retinal thick-
ness in the PDT group [11], but it has to be noted that this
study included both patients with secondary CNV and
polypoidal choroidal vasculopathy. When looking at the
MINERVA study, in which only 17 of the 119 patients
(14.3%) in the treatment arm had a CNV secondary to
CSCR, the mean number of ranibizumab injections was 5.8
injections in the ranibizumab arm at month 12. When com-
pa r i ng an t i -VEGF t r e a tmen t o f p a chycho ro i d
neovasculopathy with the treatment of neovascular AMD, re-
ports suggest that anti-VEGF treatment is equally effective in
both diseases but eyes with pachychoroid neovasculopathy
require fewer injections in the maintenance phase of the treat-
ment. However, it has to be noted that these reports partially
also included pAT1-CNV/PCV patients [18, 19]. A recently
published article compared the effect of the anti-VEGF agents
r an ib i zumab and a f l i b e r c ep t on pachycho ro id
neovasculopathy [20]. The mean number of injections was
3.5 in the aflibercept group and 4.6 in the ranibizumab group.
The results showed that aflibercept had a superior effect on
reduction of central retinal thickness and resolution of
subretinal fluid compared with ranibizumab. These findings
are well in line with those of the present study, in which the
patients treated with aflibercept initially or switched to
aflibercept showed a more marked decrease in central macular
thickness and a higher proportion of dry maculae. It has been
discussed that aflibercept might have a stronger effect on cho-
roidal hyperpermeability [21].This could be explained on the
one hand by the additional molecular targets (VEGF-B, PlGF)
and on the other hand by a different mechanism of uptake in
the tissue [22].
Central serous chorioretinopathy is a disease that common-
ly occurs in the younger age group. If neovascularization is
considered to be a complication of a chronic disease course, it
is logical that the average age in this cohort was 65 years. This
observation shows good agreement with other publications, in
which the mean age ranged between 57 and 68 years [8, 11,
17, 20].
The pathogenesis of CNV in pachychoroidal diseases is
still not fully understood. In CSCR, the areas of leakage typ-
ically lie over areas with choroidal hyperpermeability and di-
lated choroidal vessels, also named pachyvessels [23]. Flat
irregular PEDs containing type 1 CNV usually emerge in
these areas of chronically stressed RPE. The role of anti-
VEGF seems to be different than in AMD as it has been
shown tha t an t i -VEGF leve l s in pachychoro id
neovasculopathy are lower than in neovascular AMD [24,
25]. In fact, high baseline anti-VEGF levels seem to be even
associated with a poor response to anti-VEGF therapy. In
chronic CSCR, proinflammatory cytokines and upregulated
angiogenesis are correlated with choroidal vessel abnormali-
ties [26]. Thus, the pathogenetic process leading to and main-
taining the CNV is dependent on VEGF and proinflammatory
cytokines, but might as well be affected by dysregulation and
hyperpermeability of choroidal vessels [12]. However, it is
unclear which pathological process is the trigger, choroidal
vessel dysregulation or inflammation or a combination of
both. Supporting the observation that the mechanism of neo-
vascularization in pachychoroid disease differs strongly from
AMD, a recent study suggested that type 1 neovascular mem-
branes in pachychoroid disease contain matured vessels that
are less likely to respond to an anti-VEGF treatment [27].
They relate this to a neovascularization pathway that was
called arteriogenesis by Spaide in 2015 [28]. As opposed to
VEGF-dependent vessel sprouting in AMD-related angiogen-
esis, arteriogenesis is reported to be induced by shear stress on
endothelial stress in small vessels. Shear stress activates
m e c h a n o t r a n s d u c e r s wh i c h i n c r e a s e ma t r i x -
metalloproteinase activity and recruit inflammatory cells to
the extracellular matrix surrounding the vessel. The remodel-
ing process results in expansion of the vessel and thickening
of the vessel wall. In our opinion, this theory represents an
explanation for the process leading to neovascularization in
pachychoroid disease: The increased choroidal perfusion
leads to shear stress in the choriocapillaris resulting in the
abovementioned extracellular remodeling. This leads to de-
struction of the Bruch membrane and arrosion of RPE cells
(stage 2 in pachychoroid disease, pigment epitheliopathy). As
a long-term complication, the arteriogenesis-derived vessels
evolve above the Bruch membrane and below the RPE level
as a type 1 CNV.
For this reason, an important treatment effect of anti-VEGF
treatment in pachychoroid disease possibly lies within the
induction of choroidal thinning which may be a surrogate
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parameter for the reduction of choroidal hyperpermeability.
Studies on the effect of anti-VEGF therapy in non-
neovascular CSCR could show that anti-VEGF therapy can
lead to less subretinal fluid and induce choroidal thinning [29,
30]. It has to be noted, however, that thinning and reduction of
choroidal hyperpermeability might only result from long-term
anti-VEGF therapy and could thus not be achieved with an
application of only one to three injections. In our collective, a
significant reduction of mean subfoveal choroidal thickness
was noticeable already after three injections, which, however,
was markedly increased after an extended upload of six injec-
tions. Furthermore, a significantly higher percentage of “dry
macula” was observed after six (52%) than after three (19%)
injections. The effect of choroidal thinning by a long-term
anti-VEGF therapy has been also reported in other studies
[18, 20, 31]. Subretinal fluid might be both caused by the
underlying pachychoroid and the CNV. Taking this into ac-
count as well as the fact that all patients of this collective had
CSCR before, it is reasonable that a reduction in choroidal
thickness may also lead to less subretinal fluid and thus to a
reduced central macular thickness.
Vice versa, another issue that needs further discussion
is nonresponse. In our collective, a complete resolution of
subretinal fluid was achieved in 52.4% of the eyes after
six injections, meaning that 47.6% still had significant
fluid in spite of half a year of intense anti-VEGF therapy.
For nonresponders of anti-VEGF therapy, it has been
shown that, analogously to the treatment of pAT1-CNV/
PCV, an adjunctive photodynamic therapy can lead to
complete absorption of the subretinal fluid [32].
Moreover, photodynamic therapy has proven to be an ef-
fective therapy in non-neovascular CSCR [33, 34].
Therefore, it is pivotal for the understanding of treatment
responses that in pachychoroid disorders, subretinal fluid
can be both caused by the CNV or the choroidal
hyperpermeability. To underline this, it should be men-
tioned that in our collective, all patients had a decrease
in PED thickness. This means that in all patients, the
CNV actually responded to the anti-VEGF treatment but
not all patients had a subsequent reduction of subretinal
fluid. Taking all this into consideration, resolution of
subretinal fluid is possibly not the ideal endpoint for a
successful treatment of the CNV.
The limitations of the current study are mainly related to
the retrospective design and relatively small sample size.
Nonetheless, the size of the sample was large enough to apply
the intended statistical tests. A limitation regarding multimod-
al imaging was the fact that data of optical coherence tomog-
raphy angiography was not sufficient to conduct measure-
ments to all corresponding OCT images and injection time
points. Therefore, we had to focus the analysis of anatomical
remodeling on OCT-B-scan features. Given the fact that
CSCR is often complicated or even caused by the
administration of steroid medication, a further limitation of
this study lies in the missing data on steroid history. As men-
tioned above, there was proof of a recent steroid use in one
patient. However, it must also be taken into account that many
patients after a long course of disease do not remember wheth-
er the administration of steroids triggered their first episode.
The collective of this analysis represents real-life data. This is
why the intended monthly injection interval was not perfectly
achieved. The mean interval between the injections of 34.2 ±
3.1 days indicates a good therapy adherence in this collective,
taking into account the data from the MINERVA study, in
which at 12 months, the mean number of injections in the
treatment group was only 5.8 of a possible 10 injections.
Due to the non-trial conditions, we decided to measure the
endpoints after six injections, not 6 months. Another limita-
tion lies in the fact that there is no 12-month follow-up data to
evaluate recurrence rates and the missing evaluation of a
maintenance phase. However, this study was designed to eval-
uate the initial treatment response, and it is the first to evaluate
the extended upload of six anti-VEGF injections.
In conclusion, we show that a strict injection regimen for
CNV complicating pachychoroid disease can lead to a favor-
able anatomical and functional treatment response which is
attributable not only to substantial effects of anti-VEGF on
VEGF-dependent CNV morphology but also to a modulation
of choroidal perfusion. In order to define standard manage-
ment recommendations, further prospective studies are how-
ever necessary.
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